{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:16:28Z","timestamp":1783350988073,"version":"3.54.6"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10637-018-0561-5","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T04:12:55Z","timestamp":1516075975000},"page":"509-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report"],"prefix":"10.1007","volume":"36","author":[{"given":"Kenta","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-9379","authenticated-orcid":false,"given":"Jiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Katakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/phar.1643","volume":"35","author":"NM La-Beck","year":"2015","unstructured":"La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB (2015) Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy 35:963\u2013976","journal-title":"Pharmacotherapy"},{"key":"561_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1574886311207040289","volume":"11","author":"A Sgambato","year":"2016","unstructured":"Sgambato A, Casaluce F, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C (2016) Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non- small cell lung cancer (NSCLC): a review on toxicity profile and its management. Curr Drug Saf 11:62\u201368","journal-title":"Curr Drug Saf"},{"key":"561_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234\u2013240","journal-title":"JAMA Oncol"},{"key":"561_CR4","volume-title":"Immune hemolytic Anemias","author":"LD Petz","year":"2004","unstructured":"Petz LD, Garratty G (2004) Immune hemolytic Anemias, 2nd edn. Churchill Livingstone, Philadelphia","edition":"2"},{"key":"561_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40425-017-0214-9","volume":"5","author":"U Khan","year":"2017","unstructured":"Khan U, Ali F, Khurram MS, Zaka A, Hadid T (2017) Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer 5:15","journal-title":"J Immunother Cancer"},{"key":"561_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CMR.0000000000000232","volume":"26","author":"BY Kong","year":"2016","unstructured":"Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS (2016) Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res 26:202\u2013204","journal-title":"Melanoma Res"},{"key":"561_CR7","volume":"4","author":"SD Phadke","year":"2016","unstructured":"Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y (2016) Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Investig Med High Impact Case Rep 4:2324709616674316","journal-title":"J Investig Med High Impact Case Rep"},{"key":"561_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765\u2013772","journal-title":"Int Immunol"},{"key":"561_CR9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","volume":"10","author":"H Nishimura","year":"1998","unstructured":"Nishimura H, Minato N, Nakano T, Honjo T (1998) Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 10:1563\u20131572","journal-title":"Int Immunol"},{"key":"561_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/intimm\/dxs098","volume":"25","author":"ML Thibult","year":"2013","unstructured":"Thibult ML, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, Chetaille B, Olive D (2013) PD-1 is a novel regulator of human B-cell activation. Int Immunol 25:129\u2013137","journal-title":"Int Immunol"},{"key":"561_CR11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550","journal-title":"Lancet"},{"key":"561_CR12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Investigators K-. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833","journal-title":"N Engl J Med"},{"key":"561_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135","journal-title":"N Engl J Med"},{"key":"561_CR14","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639","journal-title":"N Engl J Med"},{"key":"561_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3324\/haematol.2014.112813","volume":"100","author":"A Maccio","year":"2015","unstructured":"Maccio A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, Floris C, Omoto I, Barracca A, Ganz T (2015) The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 100:124\u2013132","journal-title":"Haematologica"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0561-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:20:46Z","timestamp":1678558846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0561-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0561-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,16]]},"assertion":[{"value":"10 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"N.K. has received grants and honoraria from MSD outside the submitted work. All remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the declaration of Helsinki and ethical standards of the institutional and\/or national research committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}